AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 4003284
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 to 200 mg/day)
Trial: 30921737
Drug: Enriched CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched CO2 (800 ± 40 μmol mol-1) under salt stress (80 mmol L-1 NaCl)
Trial: 30921737
Drug: Ambient CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambient CO2 (400 μmol mol-1) under salt stress (80 mmol L-1 NaCl)
Trial: 30921737
Drug: Enriched CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched CO2 (800 ± 40 μmol mol-1) under no salt stress (0 mmol L-1 NaCl)
Trial: 30921737
Drug: Ambient CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambient CO2 (400 μmol mol-1) under no salt stress (0 mmol L-1 NaCl)
Trial: 21074013
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg buccal misoprostol
Trial: 17982603
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of table sugar (Kandisin)
Trial: 15077099
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of reduced-dose reteplase and abciximab combination therapy
Trial: 15077099
Drug: Abciximab alone
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab alone administered just before PCI
Trial: 15077099
Drug: Facilitated PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated PCI treatments (reteplase/abciximab combination therapy or abciximab alone)
Trial: 22608582
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg ketamine
Trial: 3202097
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose coadministration with calcium at 222 mmol
Trial: 3202097
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose coadministration with calcium at 0 mmol (control)
Trial: 3202097
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose coadministration with calcium at 56 mmol
Trial: 3202097
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose coadministration with calcium at 444 mmol
Trial: 28359280
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (saline)
Trial: 24297189
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with pegylated interferon‐α2a (135 µg weekly) plus ribavirin (200 mg daily)
Trial: 24297189
Drug: Pegylated interferon‐α2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon‐α2a (135 µg weekly) monotherapy
Trial: 24297189
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with pegylated interferon‐α2a plus ribavirin
Trial: 24297189
Drug: Pegylated interferon‐α2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon‐α2a monotherapy
Trial: 21600688
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human luteinizing hormone (rhLH) 37.5 IU
Trial: 21600688
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human luteinizing hormone (rhLH) 75 IU
Trial: 21600688
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human follicle‐stimulating hormone (rhFSH) alone
Trial: 16764872
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment of miscarriage with 200 mg of mifepristone and 0.8 mg of misoprostol 1‐3 days after the event
Trial: 14754942
Drug: Pediatric CI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric CI therapy
Trial: 11751485
Drug: Doxorubicin 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 80 mg/m(2) as i.v. bolus followed by paclitaxel 200 mg/m(2) as a 24-h infusion and then cyclophosphamide 3.0 g/m(2) as a 1-h infusion (arm A)
Trial: 11751485
Drug: Concurrent paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent paclitaxel and cyclophosphamide at the same doses (arm B)
Trial: 9403288
Drug: Voglibose 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose 5 mg t.i.d.
Trial: 10779290
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) 30 mg/day
Trial: 19650947
Drug: Inhaled pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled pharmacotherapy
Trial: 19650947
Drug: Guidelines for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guidelines for inhaled pharmacotherapy
Trial: 10729391
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose acetylcholine
Trial: 10729391
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose acetylcholine
Trial: 10729391
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to oxidized low-density lipoprotein
Trial: 8888218
Drug: Bolus tracking
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus tracking with 120 mL of contrast material
Trial: 8888218
Drug: Fixed scanning
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed scanning delay with 120 mL of contrast material
Trial: 8888218
Drug: Bolus tracking
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus tracking with 100 mL of contrast material
Trial: 8888218
Drug: Fixed scanning
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed scanning delay with 100 mL of contrast material
Trial: 3859587
Drug: epirubicin 85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epirubicin 85 mg/m2
Trial: 3859587
Drug: doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin 60 mg/m2
Trial: 26467038
Drug: Single-injection transversus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection transversus abdominis plane (TAP) block
Trial: 23066868
Drug: Ecabet sodium
RxNorm normalized name: ecabet sodium
DrugBank: Ecabet (DB05265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecabet sodium quadruple therapy
Trial: 18822996
Drug: Subsequent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent treatment options at Levels 2-4 (randomized and open label)
Trial: 16125588
Drug: Intravenous artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous artesunate 2.4 mg/kg bodyweight given as a bolus at 0, 12, and 24 h, then daily
Trial: 11849659
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/d for 6 weeks
Trial: 11849659
Drug: Simvastatin dosage
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin dosage variations (mg/kg/day)
Trial: 12202047
Drug: Risedronate (2.5‐
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (2.5‐ and 5‐mg doses)
Trial: 9517503
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cytarabine and etoposide (HIDAC‐3‐7)
Trial: 9517503
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose combination (7‐3‐7)
Trial: 8791967
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg daily
Trial: 8038354
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg nightly
Trial: 3398651
Drug: Piroxicam cream
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam cream (0.5%, 1%, 1.5%)
Trial: 3398651
Drug: Indomethacin cream
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin cream (5%)
Trial: 3398651
Drug: Etofenamate gel
RxNorm normalized name: etofenamate
DrugBank: Etofenamate (DB08984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etofenamate gel (1%)
Trial: 3398651
Drug: Benzydamine cream
RxNorm normalized name: benzydamine
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine cream (5%)
Trial: 3398651
Drug: Piroxicam gel
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam gel (1%)
Trial: 30995824
Drug: Inulin Propionate
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin Propionate Ester (IPE) incorporated into food products (10 g/d for six days)
Trial: 25555445
Drug: Art, massage,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art, massage, or music therapy employed in hospices
Trial: 21624490
Drug: BUD/FM 320/9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD/FM 320/9 μg
Trial: 21624490
Drug: FP/SM 250/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/SM 250/50 μg
Trial: 10934666
Drug: U.S.-brand warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U.S.-brand warfarin sodium tablet (5 mg)
Trial: 10934666
Drug: Generic warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic warfarin product (5 mg)
Trial: 9795574
Drug: Health education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health education using simple line drawings of reproductive organs and signs of STDs; method not quantified in terms of dosage or duration.
Trial: 1567574
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) administered at 20 mg/kg/day plus 100 mg/kg/day for 21 days.
Trial: 1567574
Drug: Pentamidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentamidine administered at 4 mg/kg/day for 21 days.
Trial: 1567574
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in therapy due to failure to respond.
Trial: 1567574
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in therapy due to toxicity.
Trial: 29031492
Drug: Comprehensive Symptom
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive Symptom Management (CSM) which combines ASM with optimized medication management delivered by a nurse-physician specialist team and facilitated mental health care
Trial: 17608233
Drug: Yishen Yangnao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yishen Yangnao capsule
Trial: 16125497
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers (higher doses in the upper quartile)
Trial: 16125497
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers (both dosage levels)
Trial: 16125497
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers (lower doses in the lower 3 quartiles)
Trial: 12244291
Drug: levobupivacaine 0.50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine 0.50% (1 mg/kg)
Trial: 12244291
Drug: racemic bupivacaine
RxNorm normalized name: Racemic bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: racemic bupivacaine 0.50% (1 mg/kg)
Trial: 12244291
Drug: ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.75% (1.4 mg/kg)
Trial: 9096446
Drug: Conventional heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional heparin
Trial: 7272152
Drug: Atropine and
RxNorm normalized name: atropine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine and Metoclopramide (combined administration)
Trial: 21751879
Drug: Topical N-acetyl-cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical N-acetyl-cysteine (NAC) 5%
Trial: 21751879
Drug: Topical steroid-antibiotic
RxNorm normalized name: Betadine Antibiotic Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid-antibiotic combination (betamethasone 0.1%-sulfacetamide sodium 10%)
Trial: 17513628
Drug: Repeat dose
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat dose of ondansetron 4 mg
Trial: 9438895
Drug: Granisetron 0.1
RxNorm normalized name: granisetron 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 0.1 mg
Trial: 15118190
Drug: 6.4% carbohydrate‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4% carbohydrate‐electrolyte (CHO) solution
Trial: 15118190
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) solution
Trial: 3182111
Drug: May and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: May and Baker preparation of metronidazole (200 mg)
Trial: 3182111
Drug: Servipharm preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Servipharm preparation of metronidazole (200 mg)
Trial: 3182111
Drug: May and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: May and Baker preparation of metronidazole
Trial: 3182111
Drug: Servipharm preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Servipharm preparation of metronidazole
Trial: 30374191
Drug: Buprenorphine/samidorphan (BUP/SAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/samidorphan (BUP/SAM) 2 mg/2 mg
Trial: 23704060
Drug: Dobutamine stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine stress MR imaging (DS‐MR) at 10 μg/kg/min and 20 μg/kg/min
Trial: 17990453
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with compound Reinhartdt and Sea Cumber Capsule (RSC) and Donepezil
Trial: 16359481
Drug: Carboxymethyl cellulose
RxNorm normalized name: Carboxymethyl cellulose
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxymethyl cellulose (CC) adhesive paste
Trial: 9820719
Drug: Low flow-rate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flow-rate (LFR) group with 2.5 L/min insufflation
Trial: 9820719
Drug: High flow-rate
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow-rate (HFR) group with 7.5 L/min insufflation
Trial: 30375187
Drug: O-R electric
RxNorm normalized name: OSTOMY SET,STERILE O.R.GUARDIAN H#4673
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-R electric toothbrush with novel round brush head (EB60) on an Oral-B Vitality O-R handle (D12)
Trial: 28193616
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of betamethasone valerate 0.1% cream twice a day for 6 weeks
Trial: 25297572
Drug: Glibenclamide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (2.5 mg) tablets twice daily
Trial: 17053552
Drug: Spironolactone 25-50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25-50 mg once daily
Trial: 15525445
Drug: Desmopressin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (0.2 microg) administered intravenously
Trial: 15525445
Drug: Piroxicam administered
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam administered to achieve steady state
Trial: 15525445
Drug: Desmopressin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (2 microg) administered intravenously
Trial: 2192099
Drug: Abana (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abana (800 mg tds)
Trial: 2192099
Drug: Methyldopa (M-DOPA,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (M-DOPA, 250 mg tds)
Trial: 457528
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and dipyridamole premedication after 3 days
Trial: 457528
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication after 3 days
Trial: 31781694
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) gel applied topically on the day of frenectomy and on days 3, 7, and 14 postoperatively
Trial: 31781694
Drug: No application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No application of HA gel (Control)
Trial: 31690647
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioural therapy (iCBT) consisting of seven weekly modules with support from a web therapist.
Trial: 31690647
Drug: Care as
RxNorm normalized name: TopCare Aspirin 325mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Care as usual (CAU) with no constraints regarding the range of treatments.
Trial: 24220935
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg/day (oral) in repeated cycles of 4-week on/2-week off schedule
Trial: 24220935
Drug: Interferon-α (IFN-α)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-α (IFN-α) 9 million units subcutaneously thrice weekly
Trial: 19066303
Drug: GH bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH bolus administered postabsorptively
Trial: 19066303
Drug: GH bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH bolus administered in the fasting state (37.5 h)
Trial: 17469890
Drug: 8-week hypnotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-week hypnotic taper program with self-help CBT
Trial: 17469890
Drug: 8-week hypnotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-week hypnotic taper program alone
Trial: 16045027
Drug: Two-stage administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-stage administration sedation method (with propofol plus midazolam)
Trial: 16045027
Drug: Routine continuum
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine continuum administration sedation method
Trial: 8585734
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of ofloxacin i.v. q12h
Trial: 8585734
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of ciprofloxacin i.v. q12h
Trial: 8585734
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of ofloxacin i.v. q12h plus 1 g of ceftazidime i.v. q8h
Trial: 8585734
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of ciprofloxacin i.v. q12h plus 1 g of ceftazidime i.v. q8h
Trial: 8585734
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of ofloxacin i.v. q12h plus 4 g of piperacillin i.v. q8h
Trial: 8585734
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of ciprofloxacin i.v. q12h plus 4 g of piperacillin i.v. q8h
Trial: 2376426
Drug: Preparation A
RxNorm normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation A (200 mg ibuprofen)
Trial: 2376426
Drug: Preparation B
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation B (200 mg ibuprofen)
Trial: 6158257
Drug: Amipaque (metrizamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amipaque (metrizamide 370 mg I/ml)
Trial: 6158257
Drug: Isopaque Coronar
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isopaque Coronar (metrizoate 370 mg I/ml)
Trial: 30905265
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT) as part of the IAPT initiative